BusinessApellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 2, 2018, 12:00 PM UTC
BusinessApellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2By Nasdaq OMXDec 20, 2017, 10:30 PM UTC
BusinessApellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial OfficerBy Nasdaq OMXDec 19, 2017, 3:16 PM UTC
BusinessApellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)By Nasdaq OMXDec 8, 2017, 9:34 PM UTC
BusinessApellis Pharmaceuticals Announces Closing of its Initial Public OfferingBy Nasdaq OMXNov 13, 2017, 9:05 PM UTC
BusinessApellis Pharmaceuticals Announces Pricing of Initial Public OfferingBy Nasdaq OMXNov 9, 2017, 2:38 AM UTC
BusinessApellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNHBy Nasdaq OMXDec 2, 2016, 1:00 PM UTC
BusinessApellis to Present Safety and Efficacy Data from Clinical Trials of APL-2 in PNH at December Scientific MeetingsBy Nasdaq OMXNov 21, 2016, 1:00 PM UTC
